We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

AstraZeneca Slaps Biovail Over Seroquel XR

Law360 (January 13, 2009, 12:00 AM EST) -- In its latest bid to protect two patents for Seroquel XR, AstraZeneca Pharmaceuticals LP has hit Biovail Corp. and two subsidiaries with an infringement suit over the popular treatment for bipolar disorder and schizophrenia.

The complaint, filed Friday in the U.S. District Court for the District of New Jersey, alleges that Biovail's submission of an abbreviated new drug application for an extended-release version of quetiapine fumarate to the U.S. Food and Drug Administration infringes AstraZeneca's patents.

The patents-at-issue are U.S. Patent Numbers 4,879,288 and 5,948,437, which...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.